NBIX
Neurocrine Biosciences, Inc.$170.83-1.22 (-0.71%)Prev Close$172.04·MCap$17.81B·P/E36.94·Vol551.2K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
28
$96.34M
◆
Net Activity
Net Seller
$96.34M
●
Active Insiders
14
last 12 mo
Over the past 12 months, insider activity at Neurocrine Biosciences, Inc. (NBIX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 28 insider sales totaling $96.34M. The most recent insider transaction was by Lippoldt Darin (officer: Chief Legal Officer), who sold $1.80M worth of shares on Jul 13, 2026. Neurocrine Biosciences, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $17.81B.
NBIX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 13, 2026 | Lippoldt Darin | officer: Chief Legal Officer | Sell | 10,000 | $179.60 | $1.80M | 54,729 |
| Jul 13, 2026 | Delaet Ingrid | officer: Chief Regulatory Officer | Sell | 4,367 | $181.02 | $790.5K | 16,225 |
| Jul 9, 2026 | Delaet Ingrid | officer: Chief Regulatory Officer | Sell | 14,571 | $178.65 | $2.60M | 16,225-47% |
| Jun 30, 2026 | Lippoldt Darin | officer: Chief Legal Officer | Sell | 10,000 | $170.15 | $1.70M | 54,729 |
| Jun 9, 2026 | SHERWIN STEPHEN A | director | Sell | 25,000 | $165.32 | $4.13M | 32,977-43% |
| Jun 8, 2026 | Norwalk Leslie V | director | Sell | 1,250 | $168.06 | $210.1K | 2,838-31% |
| Jun 4, 2026 | Cooke Julie | officer: Chief Human Resources Officer | Sell | 36,937 | $156.22 | $5.77M | 45,097-45% |
| Jun 2, 2026 | Delaet Ingrid | officer: Chief Regulatory Officer | Sell | 2,261 | $156.71 | $354.3K | 16,225 |
| Jun 2, 2026 | Onyia Jude | officer: Chief Scientific Officer | Sell | 11,000 | $160.25 | $1.76M | 25,846-30% |
| May 29, 2026 | Onyia Jude | officer: Chief Scientific Officer | Sell | 11,000 | $155.53 | $1.71M | 25,846-30% |
| May 28, 2026 | Boyer David W. | officer: Chief Corp. Affairs Officer | Sell | 3,888 | $156.64 | $609.0K | 7,799-33% |
| May 21, 2026 | GORMAN KEVIN CHARLES | director | Sell | 245,088 | $154.33 | $37.82M | 511,293-32% |
| May 18, 2026 | POPS RICHARD F | director | Sell | 15,000 | $157.65 | $2.36M | 34,480-30% |
| May 14, 2026 | Norwalk Leslie V | director | Sell | 3,810 | $155.01 | $590.6K | 2,429-61% |
| Feb 17, 2026 | GORMAN KEVIN CHARLES | Director | Sell | 40,305 | $124.12 | $5.00M | 0 |
| Feb 12, 2026 | Onyia Jude | Chief Scientific Officer | Sell | 15,099 | $124.02 | $1.87M | 0 |
| Feb 12, 2026 | ABERNETHY MATT | Chief Financial Officer | Sell | 3,746 | $123.81 | $463.8K | 0 |
| Feb 12, 2026 | BENEVICH ERIC | Chief Commercial Officer | Sell | 12,227 | $124.03 | $1.52M | 0 |
| Feb 12, 2026 | Boyer David W. | Chief Corp. Affairs Officer | Sell | 8,052 | $124.01 | $998.5K | 0 |
| Feb 12, 2026 | Cooke Julie | Chief Human Resources Officer | Sell | 2,320 | $123.79 | $287.2K | 0 |
| Feb 12, 2026 | Delaet Ingrid | Chief Regulatory Officer | Sell | 1,615 | $123.56 | $199.6K | 0 |
| Feb 12, 2026 | Gano Kyle | Chief Executive Officer | Sell | 2,648 | $123.10 | $326.0K | 0 |
| Feb 12, 2026 | Lippoldt Darin | Chief Legal Officer | Sell | 2,056 | $123.64 | $254.2K | 0 |
| Jan 20, 2026 | Gano Kyle | director, officer: Chief Executive Officer | Sell | 36,400 | $132.70 | $4.83M | 140,407 |
| Nov 26, 2025 | MORROW GEORGE J | Director | Sell | 15,000 | $143.37 | $2.15M | 7,068-68% |
| Nov 6, 2025 | RASTETTER WILLIAM H | Director | Sell | 18,000 | $151.82 | $2.73M | 40,360-31% |
| Nov 4, 2025 | Gano Kyle | Chief Executive Officer | Sell | 300 | $141.97 | $42.6K | 140,407 |
| Aug 11, 2025 | GORMAN KEVIN CHARLES | Director | Sell | 106,322 | $126.41 | $13.44M | 514,596 |
| Jul 11, 2025 | Delaet Ingrid | Chief Regulatory Officer | Sell | 457 | $135.00 | $61.7K | 4,730 |
| Jul 11, 2025 | Onyia Jude | Chief Scientific Officer | Sell | 59,819 | $130.46 | $7.80M | 18,289-77% |
| Jul 7, 2025 | Onyia Jude | Chief Scientific Officer | Sell | 20,362 | $130.13 | $2.65M | 18,289-53% |
| May 29, 2025 | GORMAN KEVIN CHARLES | Director | Sell | 9,613 | $120.38 | $1.16M | 514,596 |
| May 7, 2025 | RASTETTER WILLIAM H | Director | Sell | 30,000 | $110.20 | $3.31M | 37,491-44% |
| Feb 14, 2025 | ABERNETHY MATT | Chief Financial Officer | Sell | 2,558 | $116.86 | $298.9K | 35,810 |
| Feb 14, 2025 | BENEVICH ERIC | Chief Commercial Officer | Sell | 2,154 | $116.73 | $251.4K | 44,689 |
| Feb 14, 2025 | Boyer David W. | Chief Corp. Affairs Officer | Sell | 1,785 | $116.74 | $208.4K | 3,565-33% |
| Feb 14, 2025 | Cooke Julie | Chief Human Resources Officer | Sell | 1,551 | $116.78 | $181.1K | 20,190 |
| Feb 14, 2025 | Delaet Ingrid | Chief Regulatory Officer | Sell | 1,471 | $116.71 | $171.7K | 4,730 |
| Feb 14, 2025 | Gano Kyle | Chief Executive Officer | Sell | 2,558 | $116.85 | $298.9K | 139,907 |
| Feb 14, 2025 | GORMAN KEVIN CHARLES | Director | Sell | 5,844 | $116.69 | $681.9K | 524,209 |
| Feb 14, 2025 | Lippoldt Darin | Chief Legal Officer | Sell | 2,184 | $116.75 | $255.0K | 43,405 |
| Feb 14, 2025 | Onyia Jude | Chief Scientific Officer | Sell | 2,879 | $116.79 | $336.2K | 18,089 |
| Feb 14, 2025 | ROBERTS EIRY | Chief Medical Officer | Sell | 2,218 | $116.44 | $258.3K | 35,640 |
| Feb 14, 2025 | SHERWIN STEPHEN A | Director | Sell | 13,831 | $116.69 | $1.61M | 10,673-56% |
| Feb 12, 2025 | ABERNETHY MATT | Chief Financial Officer | Sell | 980 | $118.27 | $115.9K | 33,561 |
| Feb 12, 2025 | BENEVICH ERIC | Chief Commercial Officer | Sell | 980 | $118.31 | $115.9K | 42,799 |
| Feb 12, 2025 | Boyer David W. | Chief Corp. Affairs Officer | Sell | 700 | $118.31 | $82.8K | 1,998-26% |
| Feb 12, 2025 | Cooke Julie | Chief Human Resources Officer | Sell | 700 | $118.28 | $82.8K | 18,831 |
| Feb 12, 2025 | Gano Kyle | Chief Executive Officer | Sell | 980 | $118.39 | $116.0K | 137,658 |
| Feb 12, 2025 | GORMAN KEVIN CHARLES | Director | Sell | 2,274 | $118.37 | $269.2K | 519,074 |
Showing 1–50 of 233
1 / 5
NBIX Insider Buying Activity
The following table shows recent insider purchases of Neurocrine Biosciences, Inc. (NBIX) stock reported via SEC Form 4 filings.
No insider buying activity found for NBIX in the last 12 months.
NBIX Insider Selling Activity
The following table shows recent insider sales of Neurocrine Biosciences, Inc. (NBIX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 13, 2026 | Lippoldt Darin | officer: Chief Legal Officer | Sell | 10,000 | $179.60 | $1.80M | 54,729 |
| Jul 13, 2026 | Delaet Ingrid | officer: Chief Regulatory Officer | Sell | 4,367 | $181.02 | $790.5K | 16,225 |
| Jul 9, 2026 | Delaet Ingrid | officer: Chief Regulatory Officer | Sell | 14,571 | $178.65 | $2.60M | 16,225-47% |
| Jun 30, 2026 | Lippoldt Darin | officer: Chief Legal Officer | Sell | 10,000 | $170.15 | $1.70M | 54,729 |
| Jun 9, 2026 | SHERWIN STEPHEN A | director | Sell | 25,000 | $165.32 | $4.13M | 32,977-43% |
| Jun 8, 2026 | Norwalk Leslie V | director | Sell | 1,250 | $168.06 | $210.1K | 2,838-31% |
| Jun 4, 2026 | Cooke Julie | officer: Chief Human Resources Officer | Sell | 36,937 | $156.22 | $5.77M | 45,097-45% |
| Jun 2, 2026 | Delaet Ingrid | officer: Chief Regulatory Officer | Sell | 2,261 | $156.71 | $354.3K | 16,225 |
| Jun 2, 2026 | Onyia Jude | officer: Chief Scientific Officer | Sell | 11,000 | $160.25 | $1.76M | 25,846-30% |
| May 29, 2026 | Onyia Jude | officer: Chief Scientific Officer | Sell | 11,000 | $155.53 | $1.71M | 25,846-30% |
| May 28, 2026 | Boyer David W. | officer: Chief Corp. Affairs Officer | Sell | 3,888 | $156.64 | $609.0K | 7,799-33% |
| May 21, 2026 | GORMAN KEVIN CHARLES | director | Sell | 245,088 | $154.33 | $37.82M | 511,293-32% |
| May 18, 2026 | POPS RICHARD F | director | Sell | 15,000 | $157.65 | $2.36M | 34,480-30% |
| May 14, 2026 | Norwalk Leslie V | director | Sell | 3,810 | $155.01 | $590.6K | 2,429-61% |
| Feb 17, 2026 | GORMAN KEVIN CHARLES | Director | Sell | 40,305 | $124.12 | $5.00M | 0 |
| Feb 12, 2026 | Onyia Jude | Chief Scientific Officer | Sell | 15,099 | $124.02 | $1.87M | 0 |
| Feb 12, 2026 | ABERNETHY MATT | Chief Financial Officer | Sell | 3,746 | $123.81 | $463.8K | 0 |
| Feb 12, 2026 | BENEVICH ERIC | Chief Commercial Officer | Sell | 12,227 | $124.03 | $1.52M | 0 |
| Feb 12, 2026 | Boyer David W. | Chief Corp. Affairs Officer | Sell | 8,052 | $124.01 | $998.5K | 0 |
| Feb 12, 2026 | Cooke Julie | Chief Human Resources Officer | Sell | 2,320 | $123.79 | $287.2K | 0 |
| Feb 12, 2026 | Delaet Ingrid | Chief Regulatory Officer | Sell | 1,615 | $123.56 | $199.6K | 0 |
| Feb 12, 2026 | Gano Kyle | Chief Executive Officer | Sell | 2,648 | $123.10 | $326.0K | 0 |
| Feb 12, 2026 | Lippoldt Darin | Chief Legal Officer | Sell | 2,056 | $123.64 | $254.2K | 0 |
| Jan 20, 2026 | Gano Kyle | director, officer: Chief Executive Officer | Sell | 36,400 | $132.70 | $4.83M | 140,407 |
| Nov 26, 2025 | MORROW GEORGE J | Director | Sell | 15,000 | $143.37 | $2.15M | 7,068-68% |
| Nov 6, 2025 | RASTETTER WILLIAM H | Director | Sell | 18,000 | $151.82 | $2.73M | 40,360-31% |
| Nov 4, 2025 | Gano Kyle | Chief Executive Officer | Sell | 300 | $141.97 | $42.6K | 140,407 |
| Aug 11, 2025 | GORMAN KEVIN CHARLES | Director | Sell | 106,322 | $126.41 | $13.44M | 514,596 |
| Jul 11, 2025 | Delaet Ingrid | Chief Regulatory Officer | Sell | 457 | $135.00 | $61.7K | 4,730 |
| Jul 11, 2025 | Onyia Jude | Chief Scientific Officer | Sell | 59,819 | $130.46 | $7.80M | 18,289-77% |
| Jul 7, 2025 | Onyia Jude | Chief Scientific Officer | Sell | 20,362 | $130.13 | $2.65M | 18,289-53% |
| May 29, 2025 | GORMAN KEVIN CHARLES | Director | Sell | 9,613 | $120.38 | $1.16M | 514,596 |
| May 7, 2025 | RASTETTER WILLIAM H | Director | Sell | 30,000 | $110.20 | $3.31M | 37,491-44% |
| Feb 14, 2025 | ABERNETHY MATT | Chief Financial Officer | Sell | 2,558 | $116.86 | $298.9K | 35,810 |
| Feb 14, 2025 | BENEVICH ERIC | Chief Commercial Officer | Sell | 2,154 | $116.73 | $251.4K | 44,689 |
| Feb 14, 2025 | Boyer David W. | Chief Corp. Affairs Officer | Sell | 1,785 | $116.74 | $208.4K | 3,565-33% |
| Feb 14, 2025 | Cooke Julie | Chief Human Resources Officer | Sell | 1,551 | $116.78 | $181.1K | 20,190 |
| Feb 14, 2025 | Delaet Ingrid | Chief Regulatory Officer | Sell | 1,471 | $116.71 | $171.7K | 4,730 |
| Feb 14, 2025 | Gano Kyle | Chief Executive Officer | Sell | 2,558 | $116.85 | $298.9K | 139,907 |
| Feb 14, 2025 | GORMAN KEVIN CHARLES | Director | Sell | 5,844 | $116.69 | $681.9K | 524,209 |
| Feb 14, 2025 | Lippoldt Darin | Chief Legal Officer | Sell | 2,184 | $116.75 | $255.0K | 43,405 |
| Feb 14, 2025 | Onyia Jude | Chief Scientific Officer | Sell | 2,879 | $116.79 | $336.2K | 18,089 |
| Feb 14, 2025 | ROBERTS EIRY | Chief Medical Officer | Sell | 2,218 | $116.44 | $258.3K | 35,640 |
| Feb 14, 2025 | SHERWIN STEPHEN A | Director | Sell | 13,831 | $116.69 | $1.61M | 10,673-56% |
| Feb 12, 2025 | ABERNETHY MATT | Chief Financial Officer | Sell | 980 | $118.27 | $115.9K | 33,561 |
| Feb 12, 2025 | BENEVICH ERIC | Chief Commercial Officer | Sell | 980 | $118.31 | $115.9K | 42,799 |
| Feb 12, 2025 | Boyer David W. | Chief Corp. Affairs Officer | Sell | 700 | $118.31 | $82.8K | 1,998-26% |
| Feb 12, 2025 | Cooke Julie | Chief Human Resources Officer | Sell | 700 | $118.28 | $82.8K | 18,831 |
| Feb 12, 2025 | Gano Kyle | Chief Executive Officer | Sell | 980 | $118.39 | $116.0K | 137,658 |
| Feb 12, 2025 | GORMAN KEVIN CHARLES | Director | Sell | 2,274 | $118.37 | $269.2K | 519,074 |
NBIX Insiders
Similar Stocks to NBIX
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B